sGC 1061

Drug Profile

sGC 1061

Alternative Names: Nitric oxide mimetic (sGC-1061); Nomethiazoles (NO-chimera prodrugs) - sGC Pharma; sGC-1061; Sustained-release sGC-1061

Latest Information Update: 31 Mar 2016

Price : $50

At a glance

  • Originator Queens University; University of Illinois
  • Developer sGC Pharma
  • Class Antidementias; Thiazoles
  • Mechanism of Action Amyloid beta-protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 16 Jul 2012 Preclinical trials in Alzheimer's disease in USA (controlled release)
  • 31 Dec 2010 Phase-I clinical trials in Alzheimer's disease in USA (unspecified route)
  • 05 Dec 2008 Preclinical trials in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top